Cargando…

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

BACKGROUND: Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME) and geno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molinero, Luciana, Li, Yijin, Chang, Ching-Wei, Maund, Sophia, Berg, Maureen, Harrison, Jeanne, Fassò, Marcella, O’Hear, Carol, Hegde, Priti, Emens, Leisha A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813065/ https://www.ncbi.nlm.nih.gov/pubmed/31647026 http://dx.doi.org/10.1186/s40425-019-0740-8

Ejemplares similares

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
por: Emens, Leisha A, et al.
Publicado: (2021)

Beyond evolution : human nature and the limits of evolutionary explanation /
por: O’Hear, Anthony
Publicado: (1997)

Introduction to the philosophy of science
por: O’Hear, Anthony
Publicado: (1989)

Introduction to the philosophy of science
por: O'Hear, Anthony
Publicado: (1989)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

Toward integrative cancer immunotherapy: targeting the tumor microenvironment
por: Emens, Leisha A, et al.
Publicado: (2012)

It’s TIME for a biomarker-driven approach to cancer immunotherapy
por: Emens, Leisha A.
Publicado: (2016)

Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2022)

A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition
por: Arulraj, Theinmozhi, et al.
Publicado: (2023)

Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer
por: Emens, Leisha A., et al.
Publicado: (2015)

LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
por: Emens, L.A., et al.
Publicado: (2020)

Targeting adenosine for cancer immunotherapy
por: Leone, Robert D., et al.
Publicado: (2018)

Direct activation of STING in the tumor microenvironment partially overcomes immune tolerance in neu-N transgenic mice
por: Foote, Jeremy, et al.
Publicado: (2015)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012
por: Sunay, Melek Erdinc, et al.
Publicado: (2013)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2022)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
por: Huseni, Mahrukh A., et al.
Publicado: (2023)

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
por: Netterberg, Ida, et al.
Publicado: (2018)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients
por: Patil, Namrata S., et al.
Publicado: (2021)

Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer
por: Mi, Haoyang, et al.
Publicado: (2020)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer
por: Wu, Bin, et al.
Publicado: (2020)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
por: Wallin, Jeffrey J., et al.
Publicado: (2016)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
por: Sharmni Vishnu, K., et al.
Publicado: (2022)

Cancer immunotherapy trials: leading a paradigm shift in drug development
por: Emens, Leisha A., et al.
Publicado: (2016)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2022)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
por: Tamura, Yosuke, et al.
Publicado: (2023)

Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM
por: Wong, Sandy, et al.
Publicado: (2023)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mufsnjbg5ehkqbaldsr5q418td